Conference Highlights
By Colleen Hall
With specialty medicine comprising about half of all drug spending on the market in
the United States today, the concept of getting necessary prescriptions in the hands
of patients with life-threatening illnesses can, at times, seem daunting for providers, patients, and policymakers alike. Read More ›
Immunotherapy continues to offer strong results in patients with advanced melanoma, according to data presented at the European Society for Medical Oncology (ESMO) 2024. Read More ›
Small cell lung cancer (SCLC) accounts for 15% of all lung cancer cases, with one-third of patients presenting with limited disease. Read More ›
Atezolizumab, in combination with carboplatin and etoposide, has received approval as the first-line therapy for patients diagnosed with extensive-stage small cell lung cancer, following the findings from the phase 1/3 IMpower133 trial (NCT02763579) Read More ›
Artificial intelligence holds promise for detecting lung cancer if research presented
last month at the IASLC 2024 World Conference on Lung Cancer is any indicator. Read More ›
Data presented at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer add another piece to the puzzle of people who have been diagnosed with lung cancer but have never smoked. Read More ›
The median progression-free survival was 11.14 months with ivonescimab and 5.85 months with pembrolizumab (Hazard Ratio [HR], 0.51; 95% CI, 0.38-0.69; P NSCLC, and patients with brain metastases. Read More ›